A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

This study, called VOYAGER, is a bit different from what you might usually think of as a clinical trial. Instead of testing a new medicine or giving patients a specific treatment plan, it's designed to learn from peoples' real-life experiences. Think of it like gathering information on how certain eye medicines are actually used and how well they work for patients with specific eye conditions in their normal visits to the eye doctor.

The main goal is to understand the long-term effects, both good and bad, of Roche's eye medicines, Faricimab and the Port Delivery System with Ranibizumab. These medicines are used for serious eye conditions like wet age-related macular degeneration (nAMD), diabetic macular edema (DME), and different types of retinal vein occlusion (RVO). The study wants to see how these treatments perform over a longer period, what doctors consider when choosing these treatments, and how patients' vision changes. Importantly, this study won't ask you to do anything different from your usual care; your doctor will continue to make all decisions about your treatment.

By gathering this 'real-world' information from many different patients across various countries, the researchers hope to gain a much deeper insight into these eye conditions and their treatments. This kind of study helps us understand how medicines work for a wider range of people than just those in highly controlled trials. The knowledge gained could help improve future understanding and care for people with these conditions, without directly changing your personal treatment.